EUCTR2005-004034-41-DK进行中（未招募）1 期
Evaluation of Skeletal Myoblast Transplant for Treating Ischemic Heart Failure Phase 2 Study Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) Study - MAGIC
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must meet the following criteria to be enrolled in this study:
- •1.Patient must be > = 18 and < = 80 years of age.
- •2.Patient must have a recommendation for a coronary bypass, preferably with cardiopulmonary bypass support. All patients meeting this criterion may be included, including those with target injection areas that may or may not be amenable to revascularization.
- •3.Patient must have an alteration in left ventricular function, defined as an ejection fraction (EF) of < = 35% and > = 15% (determined by echocardiography and confirmed by the core laboratory).
- •4.Patient must have significant myocardial dysfunction from a previous myocardial infarction demonstrated by the existence of akinesia affecting more than 2 accessible, contiguous left ventricular segments (out of 16) on a basal state echocardiogram, with no viability after stimulation with low dose dobutamine.
- •5.The left ventricular myocardial infarction (Q wave or positive enzyme) targeted for study injections must have occurred > = 4 weeks prior to screening.
- •6.Patient must qualify for insertion of an ICD device. Patient must have an ICD upon enrollment, receive an ICD before CABG surgery and study treatment or receive an ICD prior to discharge from the hospital following CABG surgery.
- •7.Patient should be a NYHA functional class I-III, who is receiving optimal contemporary medical management (e.g., ACE inhibitors, beta-blockers, diuretics, etc.). In Canada, only patients classified as NYHA Class II or III will be eligible for enrollment.
- •8.Fertile female patients with negative urine pregnancy test at screening and on the day of treatment prior to autologous skeletal myoblast administration.
- •9.Fertile female patients who have agreed to follow an approved method of contraception to avoid pregnancy for 60 days after receiving autologous skeletal myoblast administration (or longer if required by concomitant medication (e.g., amiodarone).
- •10.Patient must be committed to following the protocol requirements for 2 years as evidenced by written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Need for a rapid surgical coronary revascularization (< = 21 days)
- •2.Need for any other related cardio-surgical measure during coronary surgery (e.g., mitral valve repair or valve replacement)
- •3.Patient with a left ventricular aneurysm who is a candidate for left ventricular aneurysmectomy or left ventricular reduction surgery
- •4.Patients receiving left or biventricular (BiV) pacing therapy for heart failure (unless the patient has stabilized after 6 or more months of this therapy)
- •5.Patient with cardiomyopathy presumed to be of non-ischemic origin (e.g., hypertrophic cardiomyopathy)
- •6.Patient for whom adequate echocardiography, or other required study procedures, cannot be performed for technical reasons
- •7.Patient for whom low dose of dobutamine, required for the identification of non-viable, scarred myocardium, is contra-indicated (e.g., recent sustained ventricular tachycardia and ventricular fibrillation)
- •8.Patient with advanced heart failure (e.g., NYHA IV heart failure symptoms, or in need of a heart transplant) who does not respond to optimal medical therapy and does not improve to at least Class III symptoms 30 days prior to skeletal muscle biopsy
- •9.Patient infected with the hepatitis C virus; the hepatitis B virus (HBs + antigen); patient who is HIV-1 or HIV-2 positive; HTLV-1 positive; Ag P24 positive (this exclusion criteria refers only to regions where this testing is required (e.g. France)
- •10.Patient with hemophilia; long-term immunosuppressive treatment, including with corticosteroids; stage III-IV arteriopathy of the lower limbs; significant muscular amyotrophia; peripheral muscular illness; serious intellectual deterioration or neuro-psychiatric disorders that would make follow-up difficult
- •11.Patient with allergies to gentamicin or other aminoglycosides, allergies to study required medications or imaging agents
- •12.Female patient who is pregnant, nursing, or fertile and using either no or an inadequate form of contraception
- •13.Illness other than ischemic heart failure that makes the short-range prognosis for survival questionable
- •14.Simultaneous participation in another study with an investigational study agent
研究者
相似试验
终止
2 期
Study to Examine the Safety and Effectiveness of Implanted Skeletal Muscle Cells (Cells Removed From the Thigh Muscle) Into Scarred Areas of Heart Muscle After Heart Attack.Ischemic Heart DiseaseIschemic CardiomyopathyIschemic Heart FailureNCT00102128Genzyme, a Sanofi Company
已完成
不适用
Evaluation of dysplastic bone transplantation in patient with McCune-Albright syndrome.McCune-Albright syndrome mandibular defectJPRN-UMIN000008745Dept. Oral and Maxillofacial Surgery, Shimane University Faculty of Medicine1
尚未招募
1 期
Evaluation of tissue-engineered hair follicles in hair lossAndrogenetic alopecia.Androgenic alopeciaIRCT20080901001159N32Skin and Stem cell Research Center of Tehran University of Medical Sciences5
撤回
2 期
Mesenchymal stromal cell (MSC) transplantation in septic shock.10027665septisch shockseptic shock and severe blood poisoning10002252NL-OMON39173Erasmus MC, Universitair Medisch Centrum Rotterdam30
进行中（未招募）
1 期
The aim of this clinical study is to show the clinical efficacy and safety of SMDCs in patients suffering from FI, and to find the optimal cell count for the functional regeneration of the external anal sphincter.Fecal incontinence in female and male patients with external anal sphincter weakness or sphincter damage.MedDRA version: 20.0Level: LLTClassification code 10016296Term: Fecal incontinenceSystem Organ Class: 100000167639EUCTR2010-021463-32-ATInnovacell Biotechnologie AG252